Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Receivables (2023)

Tango Therapeutics (TNGX) has 1 years of Change in Receivables data on record, last reported at -$2.0 million in Q1 2023.

  • For Q1 2023, Change in Receivables changed N/A year-over-year to -$2.0 million; the TTM value through Dec 2023 reached -$2.0 million, changed N/A, while the annual FY2023 figure was -$2.0 million, N/A changed from the prior year.
  • Change in Receivables reached -$2.0 million in Q1 2023 per TNGX's latest filing.
  • Across five years, Change in Receivables topped out at -$2.0 million in Q1 2023 and bottomed at -$2.0 million in Q1 2023.